Biblio

Author [ Title(Desc)] Type Year
Filters: Author is Perales, Miguel-Angel  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
I
Lucchini G, Perales M-A, Veys P. Immune reconstitution after cord blood transplantation: peculiarities, clinical implications and management strategies. Cytotherapy. 2015;17(6):711-722.
Fang J, Su Y, Zavras PD, Raval AD, Tang Y, Perales M-A, Giralt S, Stern A, Papanicolaou GA. Impact of preemptive therapy for Cytomegalovirus on hospitalizations and cost after Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2020.
Dandoy CE, Kim S, Chen M, Ahn KWoo, Ardura MI, Brown V, Chhabra S, Díaz MÁngel, Dvorak C, Farhadfar N, et al. Incidence, Risk Factors, and Outcomes of Patients Who Develop Mucosal Barrier Injury-Laboratory Confirmed Bloodstream Infections in the First 100 Days After Allogeneic Hematopoietic Stem Cell Transplant. JAMA Netw Open. 2020;3(1):e1918668.
L
Törlén J, Ringdén O, Le Rademacher J, Batiwalla M, Chen J, Erkers T, Ho V, Kebriaei P, Keever-Taylor C, Kindwall-Keller T, et al. Low CD34 Dose is Associated with Poor Survival after Reduced Intensity Conditioning Allogeneic Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome. Biol Blood Marrow Transplant. 2014.
M
Peled JU, Gomes ALC, Devlin SM, Littmann ER, Taur Y, Sung AD, Weber D, Hashimoto D, Slingerland AE, Slingerland JB, et al. Microbiota as Predictor of Mortality in Allogeneic Hematopoietic-Cell Transplantation. N Engl J Med. 2020;382(9):822-834.
O
Rodriguez N, Lee J, Flynn L, Murray F, Devlin SM, Soto C, Cho C, Dahi P, Giralt S, Perales M-A, et al. Oral Proteasome Inhibitor Ixazomib for Switch-Maintenance Prophylaxis of Recurrent or Late Acute and Chronic Graft-versus-Host Disease after Day 100 in Allogeneic Stem Cell Transplantation. Transplant Cell Ther. 2021.
Wudhikarn K, King AC, Geyer MBlaine, Roshal M, Bernal Y, Gyurkocza B, Perales M-A, Park JH. Outcomes of Relapsed B-Cell Acute Lymphoblastic Leukemia After Sequential Treatment with Blinatumomab and Inotuzumab. Blood Adv. 2022.
P
Ahmed N, Wesson W, Mushtaq MUmair, Porter DL, Nasta SD, Brower J, Bachanova V, Hu M, Nastoupil LJ, Oluwole OO, et al. Patient Characteristics and Outcomes of Outpatient Tisagenlecleucel (tisa-cel) Recipients for B Cell Non-Hodgkin Lymphoma. Transplant Cell Ther. 2023.
Nikiforow S, Frigault MJ, Frey NV, Gardner RA, Komanduri KV, Perales M-A, Kebriaei P, Warkentin PIrene, Pasquini M, Aho JLynn, et al. Paving the Road for CAR-Ts: ASTCT 80/20 Task Force consensus on challenges and solutions to improving efficiency of clinical center certification and maintenance of operations for commercially approved immune effector cell therapies. Transplant Cell Ther. 2023.
Singh A, Dandoy CE, Chen M, Kim S, Mulroney CM, Kharfan-Dabaja MA, Ganguly S, Maziarz RT, Kanakry CG, Kanakry JA, et al. Post-Transplant cyclophosphamide is associated with increase in Non-CMV Herpesvirus infections in Acute leukemia and MDS patients. Transplant Cell Ther. 2021.
Bolaños-Meade J, Hamadani M, Wu J, Malki MMAl, Martens MJ, Runaas L, Elmariah H, Rezvani AR, Gooptu M, Larkin KT, et al. Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis. N Engl J Med. 2023;388(25):2338-2348.
Saber W, Steinert P, Zhang M-J, Chen M, Pope A, Keating A, Wingard JR, Ballen K, Stiff P, Perales M-A, et al. A prospective cohort study comparing long-term outcomes with and without palifermin in patients receiving hematopoietic cell transplantation for hematologic malignancies. Transplant Cell Ther. 2021.
R
Algwaiz G, Aljurf M, Koh M, Horowitz MM, Ljungman P, Weisdorf D, Saber W, Kodera Y, Szer J, Jawdat D, et al. Real-world issues and potential solutions in HCT during the COVID-19 pandemic: Perspectives from the WBMT and the CIBMTR's Health Services and International Studies Committee. Biol Blood Marrow Transplant. 2020.
Nath K, Peterson K, Brown S, Devlin S, Rodriguez N, Barker J, Giralt S, Gyurkocza B, Jakubowski A, Papadopoulos E, et al. Reduced Intensity Compared to Non-myeloablative Conditioning in Patients with Non-Hodgkin Lymphoma undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Transplant Cell Ther. 2023.
Zhou Z, Nath R, Cerny J, Wang H-L, Zhang M-J, Abdel-Azim H, Agrawal V, Ahmed G, A Al-Homsi S, Aljurf M, et al. Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. Blood Adv. 2020;4(13):3180-3190.
Brambilla CZuanelli, Lobaugh SM, Ruiz JD, Dahi PB, Goldberg AD, Young JW, Gyurkocza B, Shaffer BC, Ponce DM, Tamari R, et al. Relapse after allogeneic stem cell transplantation of acute myeloid leukemia and myelodysplastic syndrome and importance of second cellular therapy. Transplant Cell Ther. 2021.
L Dupuis L, Quinones CM, Ritchie J, Carpenter PA, Bauters T, Yeh RF, Anasetti C, Boelens JJ, Hamerschlak N, Hassan M, et al. Response to Kawedia et al Letter to Editor in Response to the Article by McCune Et Al "Harmonization of Busulfan Plasma Exposure Unit (BPEU): A Community-Initiated Consensus Statement". Biol Blood Marrow Transplant. 2020.
Im A, Rashidi A, Wang T, Hemmer M, MacMillan ML, Pidala J, Jagasia M, Pavletic S, Majhail NS, Weisdorf D, et al. Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide. Biol Blood Marrow Transplant. 2020.
S
Neofytos D, Huang Y-T, Cheng K, Cohen N, Perales M-A, Barker J, Giralt S, Jakubowski A, Papanicolaou G. Safety and Efficacy of Intermittent Intravenous Administration of High-Dose Micafungin. Clin Infect Dis. 2015;61(suppl 6):S652-S661.
T
Prockop SE, Hasan AN, Doubrovina E, Dahi PB, M Rodriguez-Sanchez I, Curry M, Mauguen A, Papanicolaou GA, Su Y, Yao JJ, et al. Third party CMV viral specific T-cells for refractory CMV viremia and disease after hematopoietic transplant. J Clin Invest. 2023.
DeWolf S, Elhanati Y, Nichols K, Waters NR, Nguyen CL, Slingerland JB, Rodriguez N, Lyudovyk O, Giardina PA, Kousa AI, et al. Tissue-specific features of the T cell repertoire after allogeneic hematopoietic cell transplantation in human and mouse. Sci Transl Med. 2023;15(706):eabq0476.
Morjaria S, Epstein DJ, Romero FA, Taur Y, Seo SK, Papanicolaou GA, Hatzoglou V, Rosenblum M, Perales M-A, Scordo M, et al. Toxoplasma Encephalitis in Atypical Hosts at an Academic Cancer Center. Open Forum Infect Dis. 2016;3(2):ofw070.
U
Oluwole OO, Patel AR, Vadgama S, Smith NJ, Blissett R, Feng C, Dickinson M, Johnston PB, Perales M-A. An updated cost-effectiveness analysis of axicabtagene ciloleucel in second-line large B-cell lymphoma patients in the United States. J Med Econ. 2023:1-10.
Kanate AS, Majhail N, DeFilipp ZM, Dhakal B, Dholaria B, Hamilton B, Herrera AF, Inamoto Y, Jain T, Perales M-A, et al. Updated Indications for Immune Effector Cell Therapy: 2023 Guidelines from the American Society for Transplantation and Cellular Therapy. Transplant Cell Ther. 2023.
V
Nath K, Tomas AAlarcon, Flynn J, Fein JA, Alperovich A, Anagnostou T, Batlevi CLee, Dahi PB, Fingrut WB, Giralt SA, et al. Vitamin D Insufficiency and Clinical Outcomes with Chimeric Antigen Receptor T-Cell Therapy in Large B-cell Lymphoma: Vitamin D insufficiency and CAR-T in LBCL. Transplant Cell Ther. 2022.

Pages